menu ☰
menu ˟

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Creator:

The New England Journal of Medicine

Subject Keywords: Cancer
Set: Chronic Conditions
Conditions
Cancer
Catalogue: Research and Evaluation
Other Outputs
Type: Article
Region: Northern Ireland
Description:

Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)â?"positive NSCLC.  

Date:

26/06/2017

Rights: © Public
Suggested citation:

The New England Journal of Medicine. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [Online]. Available from: http://www.thehealthwell.info/node/1097470 [Accessed: 17th October 2017].

  

View your saved citations and reading lists

Contributor:

Northern Ireland Cancer Network (NICaN)
 
Click here to view all the resources gathered from this organisation's website.